Key facts

Active Substance
Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0244/2016
PIP number
EMEA-001962-PIP01-16
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of systemic light chain amyloidosis
Route(s) of administration
Intravenous use
Contact for public enquiries

Prothena Therapeutics Limited

Ireland
Tel. +353 12362505
Fax +353 1 6865675
E-mail: patrick.murphy@prothena.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page